LAMININ RECEPTOR IN BREAST TISSUE, BENIGN AND MALIGNANT TUMORS

层粘连蛋白是基底膜的主要糖蛋白，呈饱和状态。 结合于某些肿瘤和正常细胞的表面。考查 不同类型的细胞(即人胰腺癌、黑色素瘤和 膀胱癌)通过活细胞结合技术显示 根据细胞类型的不同，每个细胞的受体为50-110,000个。在我们的 实验室，已经从人类乳房中分离出层粘连蛋白受体 癌细胞和组织及小鼠黑色素瘤细胞。受体和 随后的配基结合被认为在 肿瘤细胞附着是肿瘤侵袭转移的重要环节之一。 建议的研究旨在测量和关联层粘连蛋白受体。 乳腺组织的结合能力与临床信息。层压板 受体结合能力在良性、恶性和 正常人的乳房组织。初步研究表明， 恶性与良性病变中特异性层粘连蛋白结合活性的增强 乳房组织。这些发现暗示了一个可能的干预地点。 肿瘤侵袭的顺序。

Laminin, a major glycoprotein of basement membranes, exhibits saturable binding to the surface of certain neoplastic and normal cells. Examination of various cell types (i.e. human pancreatic carcinoma, melanoma and bladder carcinoma) via live cell binding techniques indicate the number of receptors to be 50-110,000 per cell depending on cell type. In our laboratory, the laminin receptor has been isolated from human breast carcinoma cells and tissue and mouse melanoma cells. The receptor and subsequent ligand binding have been implicated to play an important role in tumor cell attachment, one of the steps in tumor invasion and metastasis. The proposed study is designed to measure and correlate laminin receptor binding capacity of breast tissues with clinical information. Laminin receptor binding capacity markedly differs between benign, malignant and normal human breast tissue. Preliminary studies indicate a 50-fold increase in specific laminin binding activity in malignant versus benign breast tissues. These findings suggest a site for possible intervention in the sequence of tumor invasion.